Only approximately two out of 10 people in the US and three out of 10 people in Europe with certain rare, advanced blood ...

While all groups have demonstrated an inspiring level of dedication and passion, I have always been moved by patients’ ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Ascletis said it has data indicating denifanstat is 98% more effective at treating acne than sarecycline, and 178% better ...

With Axtria Ignite 2025 just around the corner, attention turns to how the life sciences industry is preparing for the next ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...